Testing two drug combinations for platinum-resistant ovarian cancer

Plain-English translation of NCT06856499 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing whether combining two oral medications — and — can safely and effectively treat ovarian cancer that has stopped responding to platinum-based chemotherapy. You would take both medications together, but on different schedules to see which combination works best and causes the fewest side effects.

Women with platinum-resistant ovarian cancer have very limited treatment options, and this medication is being studied because it may work differently than previous treatments you may have already tried, potentially offering new hope for controlling the cancer.

Do you qualify?

You likely qualify if…

you are a woman aged 18 or older
you have been diagnosed with high-grade serous or endometrioid ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
your cancer came back or progressed within 6 months of your last platinum chemotherapy (platinum-resistant disease)
you have a confirmed BRCA mutation or homologous recombination deficiency (HRD) based on genetic testing
you have already received at least one prior platinum-based chemotherapy and no more than three prior lines of treatment
you have previously received a PARP inhibitor as treatment or maintenance therapy

You likely don't qualify if…

you have received more than 3 prior lines of cancer treatment
you have not been tested for BRCA mutation or HRD status, or tested negative for both
you have never received a PARP inhibitor before
you have severely low blood cell counts, kidney problems, or liver problems

What participation looks like

You would take both medications by mouth as part of a 28-day treatment cycle. Depending on which group you are assigned to, you would either take for 5 days then have 2 days off, or for 2 days then have 5 days off — while taking continuously. The trial will monitor your health with regular blood tests and scans to check how well the treatment is working and watch for any side effects.

AI-generated summary from trial data · Jul 15, 2026 · Not medical advice

Testing two drug combinations for platinum-resistant ovarian cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations(2 sites)